SynthesisScientific reports2023
Economic burden of multidrug-resistant tuberculosis on patients and households: a global systematic review and meta-analysis.
Synthesis in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- The socioeconomic and health system determinants of financial protection indicators: a global systematic review (2008-2023).BMJ global health · 2025Pooled it
- Burden of multidrug-resistant and extensively drug-resistant tuberculosis in China, India and Russia: estimates from the GBD 2023 study.Journal of thoracic disease · 2026Article
- Household costs and health-related quality of life of childhood multidrug-resistant TB in Western Cape, South Africa.IJTLD open · 2026Article
- Direct medical costs for drug-resistant tuberculosis inpatients at the national lung hospital, Vietnam: A one-year study.Journal of public health research · 2026Article
- Economic burden of MDR/RR-TB and implementation of a treatment subsidy policy in Lishui City, China: a retrospective study following strobe guidelines.BMC health services research · 2026Article
- Photodynamic therapy: A paradigm shift in overcoming drug‑resistant tuberculosis (Review).Molecular medicine reports · 2026Review
- Explanatory Modeling of Tuberculosis Treatment Outcomes: The Role of Community Engagement and Clinical Governance.International journal of environmental research and public health · 2026Article
- Facilitating and Hindering Factors in Discharge Preparation During the Hospital-to-Home Transition Period for Newly Diagnosed Tuberculosis Patients: A Qualitative Study.Patient preference and adherence · 2026Article
- Pretreatment out-of-pocket costs for people with drug-resistant tuberculosis in Bandung, Indonesia.PloS one · 2026Article
- Inequalities in financial burden of tuberculosis among affected families across 19 low- and middle-income countries.PLOS global public health · 2026Article
- Psychosocial challenges of drug-resistant tuberculosis: A qualitative study in Deoghar, Eastern India.The Indian journal of medical research · 2026Review
- Effect of smoking on drug-resistant tuberculosis treatment outcomes and potential mechanistic pathways: a multicountry cohort study.BMJ open respiratory research · 2025Observational
- Identification of determinants of high-fidelity DNA synthesis in Mycobacterium smegmatis DnaE1 through in silico and in vivo approaches.Nucleic acids research · 2025Article
- The Effectiveness and Safety of Bedaquiline, Pretomanid, and Linezolid (BPaL)-Based Regimens for Rifampicin-Resistant Tuberculosis in Non-Trial Settings-A Prospective Cohort Study in Belarus and Uzbekistan.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025Article
- Determinants of treatment success and cost implications in MDR/RR-TB patients: a prospective cohort study in China.Scientific reports · 2025Article
- Time to inclusion of selected medicines for priority diseases in National Essential Medicines Lists compared with the WHO Model List.BMJ global health · 2025Article
- β-Aminopropioamidoximes derivatives as potential antitubercular agents against anthropozoonotic infections caused byVeterinary world · 2025Article
- Analysis of molecular resistance and associated risk factors in tuberculosis.BMC infectious diseases · 2025Article
- The next generation of drug resistant tuberculosis drug design.Future medicinal chemistry · 2025Article
- Optimising TB investments in Belarus, Moldova, Kyrgyz Republic, Tajikistan and Uzbekistan: An allocative efficiency analysis.PLOS global public health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 3 countries.
Funding
Abstract
Multidrug-resistant tuberculosis (MDR-TB) is a major health threat worldwide, causing a significant economic burden to patients and their families. Due to the longer duration of treatment and expensive second-line medicine, the economic burden of MDR-TB is assumed to be higher than drug-susceptible TB. However, the costs associated with MDR-TB are yet to be comprehensively quantified. We conducted this systematic review and meta-analysis to determine the global burden of catastrophic costs associated with MDR-TB on patients and their households. We systematically searched five databases (CINHAL, MEDLINE, Embase, Scopus, and Web of Science) from inception to 2 September 2022 for studies reporting catastrophic costs on patients and affected families of MDR-TB. The primary outcome of our study was the proportion of patients and households with catastrophic costs. Costs were considered catastrophic when a patient spends 20% or more of their annual household income on their MDR-TB diagnosis and care. The pooled proportion of catastrophic cost was determined using a random-effects meta-analysis. Publication bias was assessed using visualization of the funnel plots and the Egger regression test. Heterogeneity was assessed using I
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.